// App-Quantinova.ai

PP05-4 : Liraglutide 3.0 Mg Reduces the Prevalence of Prediabetes and Delays Onset of Type 2 Diabetes in Overweight and Obese Adults: Results from Scale Obesity and Prediabetes, a Randomized, Double-Blind and Placebo-Controlled 56-Week Trial

Researchers

Presenter

  • F Xavier Pi-Sunyer

Principal Investigators

  • Arne Astrup

  • Ken Fujioka

  • Frank Lyons Greenway

  • Alfredo Halpern

  • Michel Krempf

  • David C Lau

  • Carel Le Roux

  • Rafael Violante Ortiz

  • Christine Bjorn Jensen

  • John Wilding

Medical Centers

  • Pennington Biomedical Research Center, Baton Rouge, LA.

  • St. Luke's Roosevelt Hospital, New York, NY

  • University College Dublin, Dublin 4, Ireland

  • Hopital Nord - Laennec, Nantes, France

  • University of Copenhagen, Frederiksberg, Denmark

  • University of Liverpool, Liverpool, United Kingdom

  • Scripps Clinic, La Jolla, CA.

  • Universidade de Sao Paulo (USP), Sao Paulo, Brazil

  • Instituto Mexicano del Seguro Social, Cuidad Madero, Tamaulipas, Mexico

Locations

  • Brazil

  • Canada

  • Ireland

  • United Kingdom

  • United States

  • Mexico

  • France

  • Denmark

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

  • Genetic Disorder

Disease

  • Type 2 diabetes mellitus

  • Prediabetes

  • Obesity

  • Diabetes

Biomarkers

  • Fibroblast growth factor receptor 1

  • Hemoglobin A1c

  • Body mass index

Drug/Treatment

  • Liraglutide

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved